Evaluation Levels of IL-17 and IL-10 in Serum Patients of Lung Cancer in Both Types Non-Small Cell Carcinoma and Small Cell Carcinoma in Al Najaf province/Iraq

Abstract

The current study utilized cytokines as biomarkers where play a pivotal role in the suppressive or progression of lung cancer and are used to regulate of immune response of patients with lung cancer, samples were collected from cases of patients who suffer from clinical symptoms of disease and from both sexes specifically from the center of Middle Euphrates Cancer in the government of Al-Najaf at the period from (December, 2022 to the end of March, 2023) where comprised 176 samples as 120 cases represent lung cancer and 56 cases as the apparently healthy control group, 120 cases were comprised as non-small cell carcinoma cases of patients representing 96 (80%) divided in to into 46(47.9%) cases of squamous cell carcinoma,32 cases of adenocarcinoma (33.3%), and 18 (18.7%) cases of large cell carcinoma, while 24 (20%) represented cases of small cell carcinoma, taking of blood samples from all patients cases then separated to obtain of serum for detection levels of IL-17 and IL-10 via the using of Enzyme-Linked Immunosorbent Assay (ELISA) apparatus that measured the serum levels of IL-17 in lung cancer patients and were showed (0.2309 ± 0.06659) pg/ml significantly at (p≤ 0.05) compared with the apparently healthy control group (0.1377 ± 0.0117) pg/ml, as well as it observed higher significant (p ≤ 0.05) for levels of IL-10 in patients serum (0.392 ± 0.002333) pg/ml than the apparently healthy control group(0.2089 ± 0.003074) pg/ml.